Member Info for RayPointer

To put that number into words, it is 257 trillion.

Does that mean that Bonny and Clyde were less inventive than Suzy and Kevin at making a good living?

Mass puppetry at its finest 😂

"Didn’t Captain Scarlet also have one?"

of course he did

https://cdn.animationexplore.com/thumbs/Captain-Scarlet-and-the-Mysterons-Episode-18-Shadow-of-Fear.jpg

The basis of a mass spectrometer is to take a molecule, in the case of cancer research this is normally a protein.

The molecule is ionised (i.e. , it is given an electric charge) and is then put through an electric field. The deviation of the path of the ionised molecule then indicates the mass to charge ratio of the molecule. On a protein molecule that has undergone some sort of change to the normal (e.g. via a post translational modification) this will give a different deviation as opposed to the normal unchanged protein.

The challenge then is to identify the exact difference and whether it is a viable target for a cancer drug such as a vaccine.

https://pubmed.ncbi.nlm.nih.gov/32489335/

For quite a while, Lindy has been interested in using mass spectrometry to identify viable cancer targets. From memory, she did fund a study by Durham University several years ago.

I would imagine that this approach is relevant to research into Immunobody and Moditope vaccines as well as looking for new Glycan targets.

Down 4%, surely that can't be right!

Https://horticulture.co.uk/tomatoes/moneymaker/

These tomatoes are forecast to cost £8 each

Hi chester

This link gives some indication of how much the NHS are paying for nivolumab and ipilimumab.

https://www.nice.org.uk/guidance/ta724/chapter/2-Information-about-nivolumab-with-ipilimumab-and-chemotherapy

Assuming iSCIB1+ is licenced, then I guess it is up to the pharma buying the licence as to how much they charge for iSCIB1+. I would imagine the price would be linked to how much the addition of iSCIB1+ increases the efficacy of the current standard of care. I guess if you raise the bar much higher, the price that can be charged increases and maybe this increase is not linear.

The dream scenario is that the CPIs are also enhanced by Avidimab. One cannot help dreaming 😴

"This treatment cannot be used on unresectable tumors,"

Plus it costs half a million dollars to treat one patient!

It looks like this treatment backs up Lindy's statement that pharma are now looking for proof that TILs are present.

Drac, not on its own (the numbers are too small) but as supporting evidence for the current Scope trial it surely has great relevance.

14 out of 16 were still alive after 5 years and 10 were disease free.

https://www.scancell.co.uk/scib1-iscib1

That's for late stage resected melanoma of course.

I would think that Lindy would just mention this in passing in any discussions with pharma 😂

Bermuda

Ah, yes you are correct.

I missed the following:

"The trial completed enrollment of 156 patients with advanced non-resectable or metastatic malignant melanoma in July 2022. "

It's too early in the SCOPE trial for a comparison to the UV1 results. But, if the current success continues, then Scancell should beat these results. I think Lindy did say that she would like to see some survival stats.

One thing to note is that the 2 cohorts in the UV1 trial comprised 20 and 10 patients respectively. That may be too low to attract a deal from pharma. I believe that SCIB1 + 2CPIs and iSCIB1+ + 2CPIs are both 43 patients. Lindy did say at the AGM that pharma require to see at least 30 patients in a cohort.

Talking about body fat and T Cells

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463033/

Get on it Lindy 😂

Since when is a defence of free speech classed as bullying?

Perhaps they are no longer supporters of Oxford United FC 😂

Essential: ability to perform calculations on extremely large numbers 😀

Drac, I think Redmile and Vulpes would have something to say about a cheap buyout.

"Derisory offer" is the phrase that springs to mind

It looks like myself and Bermuda were also thinking along the same lines :-)

I was thinking along the same lines Johnny.

We will probably never know what the current situation is.

The other point I would make about SC129 is that Scancell intend to trial it as a bi-specific antibody once funds permit.

That does leave other options available to pharmas e.g. Car-T or attaching an ADC as two examples.